Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 4/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | GLP1R | P43220 | 1/20 | 0.38 |
| ▸ | GPR6 | P46095 | 9/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | HTR1D | P28221 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8096393 | 0.91 | CHRM4 (0.40) | CHRM4HRH3HTR1D | |
| SCHEMBL8100848 | 0.86 | HRH3 (0.44) | CHRM4HRH3GPR6HTR1DMAOA | |
| SCHEMBL13945390 | 0.86 | AR (0.39) | CHRM4HRH3 | |
| SCHEMBL8095794 | 0.84 | HRH3 (0.58) | HRH3HTR1DMAOAMAOB | |
| SCHEMBL8087938 | 0.82 | CHRM4 (0.38) | CHRM4GPR6 | |
| SCHEMBL4242392 | 0.80 | CHRM4 (0.49) | CHRM4HRH3HTR1D | |
| SCHEMBL8095832 | 0.79 | HRH3 (0.50) | CHRM4HRH3GPR6HTR1DMAOA | |
| SCHEMBL5531637 | 0.77 | HRH3 (0.51) | HRH3GPR6HTR1D | |
| SCHEMBL13969375 | 0.76 | HTR1D (0.42) | CHRM4HRH3HTR1D | |
| SCHEMBL5532964 | 0.76 | HRH3 (0.58) | HRH3HTR1DMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023773-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-01-22 | — | — | US | disclosed |
| WO-2009000085-A1 | QUINOLINE AND QUINAZOLINE DERIVATIVES USEFUL AS MODULATORS OF GATED ION CHANNELS | PAINCEPTOR PHARMA CORPORATION (CA) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023773-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | TRPV1, TRPV2, TRPA1 | CHRM4 413/4885HRH3 1043/4885GLP1R 1977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.